Current Oncology, Volume 24, Issue 6

Background: Resource limitations affect the intensity of speech–language pathology (SLP) dysphagia interventions for patients with head-and-neck cancer (HNC). The objective of the present study was to assess the feasibility of a prospective clinical...

Background: Cancer centre Web sites can be a useful tool for distributing information about the benefits of physical activity for breast cancer (bca) survivors, and they hold potential for supporting health behaviour change. However, the extent to wh...

Introduction: Only approximately 25% of stage iv non-small-cell lung cancer (nsclc) patients receive systemic therapy. For such patients, we examined factors affecting referral to a cancer centre (cc) and to medical oncology (mo), and use of systemic...

Background: As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment—and impaired fertility in particular—are emerging as important concerns among young breast cancer survivors. Older reports have evaluated...

Background: Although high-dose interferon (hd-ifn) is the sole approved adjuvant systemic treatment for melanoma in many jurisdictions, it is toxic. We sought to assess the population-level effects of hd-ifn toxicity, particularly neuropsychiatric to...

Background: The risk of suicide is higher for patients with colorectal cancer (CRC) than for the general population. Given known differences in morbidity and sites of recurrence, we sought to compare the predictors of suicide for patients with colon...

Background: In this paper, we report on the process of strategic planning in the Radiation Medicine Program (RMP) at the Princess Margaret Cancer Centre. The RMP conducted a strategic planning exercise to ensure that program priorities reflect the cu...

Background: Data about factors driving accrual to radiation oncology trials are limited. In oncology, 30%–40% of trials are considered unsuccessful, many because of poor accrual. The goal of the present study was to inform the design of future trials...

Background: The standard first-line systemic therapy for advanced gastrointestinal stromal tumour (GIST) is imatinib. However, most GISTS develop imatinib resistance, highlighting the need for new agents in the imatinib-refractory setting. Currently,...

Objective: The purpose of this guideline is to recommend systemic therapy options for women with recurrent epithelial ovarian cancer, including fallopian tube and primary peritoneal cancers. Methods: This document updates the recommendations publishe...